<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02504723</url>
  </required_header>
  <id_info>
    <org_study_id>VGHKS11-CT10-11</org_study_id>
    <nct_id>NCT02504723</nct_id>
  </id_info>
  <brief_title>Carvedilol as an Adjunct to Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding</brief_title>
  <official_title>Carvedilol Plus Endoscopic Cyanoacrylate Injection Versus Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Veterans General Hospital.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Veterans General Hospital.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastric variceal obturation is the current endoscopic therapy of choice for gastric variceal
      bleeding but is associated with a high rebleeding rate. Carvedilol is a potent non-selective
      β-blocker. The role of carvedilol in the prevention of recurrent gastric variceal bleeding is
      not studied. This study aimed at evaluating the efficacy of carvedilol as an adjunct to
      gastric variceal obturation in the secondary prophylaxis of gastric variceal bleeding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastric variceal bleeding is a lethal complication of portal hypertension. The rebleeding
      rate ranged between 30% to 50% in patients after initial hemostasis. Endoscopic cyanoacrylate
      injection is currently the choice of endoscopic therapy of acute gastric variceal bleeding
      and prevention of recurrent bleeding. However, the rebleeding rate is still high in the
      patients undergoing repeated endoscopic cyanoacrylate injection.

      Non-selective β-blockers are frequently used for the secondary prophylaxis of variceal
      bleeding. In the case of esophageal varices, combination of non-selective β-blockers and
      endoscopic therapy significantly lowers the rebleeding rate compared with endoscopic therapy
      alone. However, propranolol failed to decrease the rebleeding rate as an adjunct to
      endoscopic cyanoacrylate injection and was associated with a higher incidence of adverse
      effects in gastric variceal bleeding patients. A more potent non-selective β-blocker than
      propranolol might further decrease portal pressure and decrease the rebleeding rate.

      Carvedilol is a potent non-selective β-blocker with both beta and alpha-1 blocker effect. It
      significantly lowers portal pressure even in propranolol non-responders. However, it is
      unclear weather carvedilol will play a role in the prevention of recurrent gastric variceal
      bleeding. The investigators conducted a randomized controlled trial to compare the efficacy
      of carvedilol combined with endoscopic cyanoacrylate injection with endoscopic cyanoacrylate
      injection alone in secondary prophylaxis of gastric variceal bleeding.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2011</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rebleeding From Gastric Varices</measure>
    <time_frame>Within 6 years</time_frame>
    <description>Rebleeding from gastric varices during the follow-up period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All Upper Gastrointestinal Bleeding</measure>
    <time_frame>Within 6 years</time_frame>
    <description>All upper gastrointestinal bleeding during the follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality or Liver Transplantation</measure>
    <time_frame>Within 6 years</time_frame>
    <description>All cause mortality or liver transplantation during the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Adverse Effects</measure>
    <time_frame>Within 6 years</time_frame>
    <description>All adverse effects during the study period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Esophageal and Gastric Varices</condition>
  <arm_group>
    <arm_group_label>Cyanoacrylate injection plus carvedilol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices. Oral carvedilol is administrated during the whole study period, starting at 6.25 mg daily and increased until the maximum tolerated dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyanoacrylate injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carvedilol</intervention_name>
    <description>Oral carvedilol is started after randomization at an initial dose of 6.25 mg daily. Doses are increased every 3 days during the admission or every 7 days in the out-patient clinics until the maximum tolerated dose was achieved or up to 25 mg daily, aiming at reducing resting pulse rate by 25 percent but not below 55 beats per minute with systolic blood pressure &gt;90 mm Hg.</description>
    <arm_group_label>Cyanoacrylate injection plus carvedilol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyanoacrylate</intervention_name>
    <description>The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.</description>
    <arm_group_label>Cyanoacrylate injection plus carvedilol</arm_group_label>
    <arm_group_label>Cyanoacrylate injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of 20 to 80 years

          -  Cirrhotic patients with acute gastric variceal bleeding proven by an endoscopy within
             24 h of bleeding

          -  Stable hemodynamic condition for at least 3 days after cyanoacrylate injection

        Exclusion Criteria:

          -  Previous treatment of gastric varices, including endoscopic therapy, transjugular
             intrahepatic porto-systemic shunt, or surgery

          -  Contraindications to non-selective beta-blockers or cyanoacrylate injection

          -  Serum total bilirubin &gt;10 mg/dL

          -  Grade III/IV hepatic encephalopathy

          -  Hepato-renal syndrome

          -  Severe heart failure (NYHA Fc III/IV)

          -  Chronic kidney disease under renal replacement therapy

          -  Refractory ascites

          -  Malignancy other than hepatocellular carcinoma

          -  Pregnancy

          -  Pacemaker use

          -  Refusal to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen-Chi Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Veterans General Hospital.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>813</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2015</study_first_submitted>
  <study_first_submitted_qc>July 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2015</study_first_posted>
  <results_first_submitted>July 4, 2017</results_first_submitted>
  <results_first_submitted_qc>July 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 27, 2017</results_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaohsiung Veterans General Hospital.</investigator_affiliation>
    <investigator_full_name>Wen-Chi Chen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Gastric varices</keyword>
  <keyword>cyanoacrylate</keyword>
  <keyword>carvedilol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cyanoacrylate Injection Plus Carvedilol</title>
          <description>The patients undergo repeated endoscopic cyanoacrylate injection every 3–4 weeks until obturation of gastric varices. Oral carvedilol is administrated during the whole study period, starting at 6.25 mg daily and increased until the maximum tolerated dose.
carvedilol: Oral carvedilol is started after randomization at an initial dose of 6.25 mg daily. Doses are increased every 3 days during the admission or every 7 days in the out-patient clinics until the maximum tolerated dose was achieved or up to 25 mg daily, aiming at reducing resting pulse rate by 25 percent but not below 55 beats per minute with systolic blood pressure &gt;90 mm Hg.
cyanoacrylate: The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.</description>
        </group>
        <group group_id="P2">
          <title>Cyanoacrylate Injection</title>
          <description>The patients undergo repeated endoscopic cyanoacrylate injection every 3–4 weeks until obturation of gastric varices.
cyanoacrylate: The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cyanoacrylate Injection Plus Carvedilol</title>
          <description>The patients undergo repeated endoscopic cyanoacrylate injection every 3–4 weeks until obturation of gastric varices. Oral carvedilol is administrated during the whole study period, starting at 6.25 mg daily and increased until the maximum tolerated dose.
carvedilol: Oral carvedilol is started after randomization at an initial dose of 6.25 mg daily. Doses are increased every 3 days during the admission or every 7 days in the out-patient clinics until the maximum tolerated dose was achieved or up to 25 mg daily, aiming at reducing resting pulse rate by 25 percent but not below 55 beats per minute with systolic blood pressure &gt;90 mm Hg.
cyanoacrylate: The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.</description>
        </group>
        <group group_id="B2">
          <title>Cyanoacrylate Injection</title>
          <description>The patients undergo repeated endoscopic cyanoacrylate injection every 3–4 weeks until obturation of gastric varices.
cyanoacrylate: The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="61"/>
            <count group_id="B3" value="121"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="60"/>
                    <count group_id="B2" value="61"/>
                    <count group_id="B3" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.52" spread="10.87"/>
                    <measurement group_id="B2" value="56.26" spread="12.08"/>
                    <measurement group_id="B3" value="56.39" spread="11.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="60"/>
                    <count group_id="B2" value="61"/>
                    <count group_id="B3" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rebleeding From Gastric Varices</title>
        <description>Rebleeding from gastric varices during the follow-up period</description>
        <time_frame>Within 6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cyanoacrylate Injection Plus Carvedilol</title>
            <description>The patients undergo repeated endoscopic cyanoacrylate injection every 3–4 weeks until obturation of gastric varices. Oral carvedilol is administrated during the whole study period, starting at 6.25 mg daily and increased until the maximum tolerated dose.
carvedilol: Oral carvedilol is started after randomization at an initial dose of 6.25 mg daily. Doses are increased every 3 days during the admission or every 7 days in the out-patient clinics until the maximum tolerated dose was achieved or up to 25 mg daily, aiming at reducing resting pulse rate by 25 percent but not below 55 beats per minute with systolic blood pressure &gt;90 mm Hg.
cyanoacrylate: The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.</description>
          </group>
          <group group_id="O2">
            <title>Cyanoacrylate Injection</title>
            <description>The patients undergo repeated endoscopic cyanoacrylate injection every 3–4 weeks until obturation of gastric varices.
cyanoacrylate: The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.</description>
          </group>
        </group_list>
        <measure>
          <title>Rebleeding From Gastric Varices</title>
          <description>Rebleeding from gastric varices during the follow-up period</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Upper Gastrointestinal Bleeding</title>
        <description>All upper gastrointestinal bleeding during the follow-up period</description>
        <time_frame>Within 6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cyanoacrylate Injection Plus Carvedilol</title>
            <description>The patients undergo repeated endoscopic cyanoacrylate injection every 3–4 weeks until obturation of gastric varices. Oral carvedilol is administrated during the whole study period, starting at 6.25 mg daily and increased until the maximum tolerated dose.
carvedilol: Oral carvedilol is started after randomization at an initial dose of 6.25 mg daily. Doses are increased every 3 days during the admission or every 7 days in the out-patient clinics until the maximum tolerated dose was achieved or up to 25 mg daily, aiming at reducing resting pulse rate by 25 percent but not below 55 beats per minute with systolic blood pressure &gt;90 mm Hg.
cyanoacrylate: The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.</description>
          </group>
          <group group_id="O2">
            <title>Cyanoacrylate Injection</title>
            <description>The patients undergo repeated endoscopic cyanoacrylate injection every 3–4 weeks until obturation of gastric varices.
cyanoacrylate: The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.</description>
          </group>
        </group_list>
        <measure>
          <title>All Upper Gastrointestinal Bleeding</title>
          <description>All upper gastrointestinal bleeding during the follow-up period</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Cause Mortality or Liver Transplantation</title>
        <description>All cause mortality or liver transplantation during the study period</description>
        <time_frame>Within 6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cyanoacrylate Injection Plus Carvedilol</title>
            <description>The patients undergo repeated endoscopic cyanoacrylate injection every 3–4 weeks until obturation of gastric varices. Oral carvedilol is administrated during the whole study period, starting at 6.25 mg daily and increased until the maximum tolerated dose.
carvedilol: Oral carvedilol is started after randomization at an initial dose of 6.25 mg daily. Doses are increased every 3 days during the admission or every 7 days in the out-patient clinics until the maximum tolerated dose was achieved or up to 25 mg daily, aiming at reducing resting pulse rate by 25 percent but not below 55 beats per minute with systolic blood pressure &gt;90 mm Hg.
cyanoacrylate: The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.</description>
          </group>
          <group group_id="O2">
            <title>Cyanoacrylate Injection</title>
            <description>The patients undergo repeated endoscopic cyanoacrylate injection every 3–4 weeks until obturation of gastric varices.
cyanoacrylate: The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality or Liver Transplantation</title>
          <description>All cause mortality or liver transplantation during the study period</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Adverse Effects</title>
        <description>All adverse effects during the study period</description>
        <time_frame>Within 6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cyanoacrylate Injection Plus Carvedilol</title>
            <description>The patients undergo repeated endoscopic cyanoacrylate injection every 3–4 weeks until obturation of gastric varices. Oral carvedilol is administrated during the whole study period, starting at 6.25 mg daily and increased until the maximum tolerated dose.
carvedilol: Oral carvedilol is started after randomization at an initial dose of 6.25 mg daily. Doses are increased every 3 days during the admission or every 7 days in the out-patient clinics until the maximum tolerated dose was achieved or up to 25 mg daily, aiming at reducing resting pulse rate by 25 percent but not below 55 beats per minute with systolic blood pressure &gt;90 mm Hg.
cyanoacrylate: The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.</description>
          </group>
          <group group_id="O2">
            <title>Cyanoacrylate Injection</title>
            <description>The patients undergo repeated endoscopic cyanoacrylate injection every 3–4 weeks until obturation of gastric varices.
cyanoacrylate: The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.</description>
          </group>
        </group_list>
        <measure>
          <title>All Adverse Effects</title>
          <description>All adverse effects during the study period</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cyanoacrylate Injection Plus Carvedilol</title>
          <description>The patients undergo repeated endoscopic cyanoacrylate injection every 3–4 weeks until obturation of gastric varices. Oral carvedilol is administrated during the whole study period, starting at 6.25 mg daily and increased until the maximum tolerated dose.
carvedilol: Oral carvedilol is started after randomization at an initial dose of 6.25 mg daily. Doses are increased every 3 days during the admission or every 7 days in the out-patient clinics until the maximum tolerated dose was achieved or up to 25 mg daily, aiming at reducing resting pulse rate by 25 percent but not below 55 beats per minute with systolic blood pressure &gt;90 mm Hg.
cyanoacrylate: The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.</description>
        </group>
        <group group_id="E2">
          <title>Cyanoacrylate Injection</title>
          <description>The patients undergo repeated endoscopic cyanoacrylate injection every 3–4 weeks until obturation of gastric varices.
cyanoacrylate: The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>poor gastric ulcer healing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>dysphagia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>chronic cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
              <event>
                <sub_title>dyspnea on exertion</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>recurrent bacteremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Wen-Chi Chen</name_or_title>
      <organization>Kaohsiung Veterans General Hospital</organization>
      <phone>886-7-3422121 ext 2139</phone>
      <email>wcchen@vghks.gov.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

